Apparently, you do not understand. You are missing the effin' point, idiot! We (SEC) does not care if wording is rebuked or refuted, that is entirely irrelevant . You do not present in a PR "results as if" when those "results" were not accumulated sufficiently as to be analyzed , ready to analyzed in the light of the norms of clinical criteria. Something can look fantastic at first blush but that is irrelevant and might DRAMATICALLY change when results are ACTUAL LY ANALYZED . You cannot present it "as though", you cannot take daily reports which are daily reports and present them as PR release as to the success, when the actual clinical data sets are NOT EVEN READY to be analyzed. That is called A) Pumping and B) INVESTIGATION . Wake up!
You really believe there is nothing illegal about a CEO pumping her own stock to retail who don't know any better? Pumping it mind you on the basis of information that is not rarely but NEVER, EVER, EVER released as factual to the analysis of the results in the context of the full clinical data sets, let alone where enrollment is far from completed, let along not knowing the full set of fact surrounding the original detail nature of the enrollment. It is one thing to release data when enrollment is completed (and the detail of the latter are known rather than having everyone guessing as to particulars that every company at this stage would have made fully known, that is one thing) but to (and listen carefully, hence the lawsuits will fly like flies on doo, doo and SEC down on her behind, to make daily reports out, again, good, bad, whatever, as representative of actual ANALYZED comparative clinical data is PLAINLY wrong. It is misleading. It is deceptive. Simply, as you will learn you cannot get away with that. You cannot make it seem as though X represents Y results when you haven't as yet fully completed enrollment and /or analyzed at certain clinical markers using actual clinical analysis. This is why the VP of Clinical research overseeing Dc VAX was not just perturbed but OUTRAGED!!!!
No, it is NOT good! Results as the VP of Anderson MD clinical research for DC VAX ( not just some "employee" lol) indicated with a mixture of utter disgust and consternation that these results were NOT yet analyzed , Get it. Daily reports on patients are daily reports. Good, bad, whatever. The release of information prior to being analyzed and released as a PR to P R O M O T E (on behalf of you dear retail idiots) her stock is not just a minor trifle but a f MAJOR violation with I assure you the full weight of the SEC on her past make do how are you Enron behind. To pass daily reports off (prior to completion of enrollment and analyzing full clinical data sets) as VP of clinical research (not the receptionist, lol) per patient and overall is not only irresponsible but can result MAJOR action not barring halting trading. altogether.
That is a S T R E T C H, shall we say? More likely she is consulting quite earnestly with her lawyers. Action (as in releasing weekly reports on patients) where enrollment of trial as to been completed and RESULTS thus not analyzed to B A S I C clinical criteria does NOT bode well for buyout but more likely scenario (in fact an unavoidable one, the case I am afraid is black and white with no shades of grey) for SEC Investigation. You simply under ANY circumstance do what she did. Hence, why the consternation from Anderson VP clinical development. This is not bashing, this is simple Fact.
Yes. agreed. But not before we test 16.35 tomorrow. If that pierces through then 15.80. We will not go below 15.00 again. Those days are over
What is HAULT, there is no "u" idiot! An dyes, Bandura was merely trying to sink the price to buy shares on the cheap, ooh now I see! LOLOL
Okay deal! I won't tell them if you don't! Hold your ear! Cover your eyes, Close your mouth! Repeat after me and rinse and repeat. See no evil, hear no evil speak evil. Are you twelve or thirteen?
Nice mentality! I'll take two! IDIOT! This is THE CLINICAL HEAD OF THEIR OWN RESEARCH TEAM OF MD AMDERSON, LOLOL
"This M.D. Anderson place may not be as "prestigious" as it's made out to be, and Linda Powers may simply be protecting the shareholders interests by being forthcoming with these preliminary releases. Sort of like a witness to a crime releases information so the "mob" doesn't kill her."
God help you!!! You should never be in the market never! First of all your attack of the head of clinical research team is not only embarrassingly ludicrous, it is risible beyond tears! You really believe "protecting shareholder interests?" In what manner, shape or form? LOL She violated the most basic tenets of the A, B, C's of clinical research trial. MORON
Well with advice like that who needs any clinical research, we will put our faith in the Lord. Remind me to send you a check for your words of wisdom, lol
And that is precisely, quite objectively , for the egregiousness and transparency of what she, LINDA darling did the SEC should (probably will) halt the trial or demand that it be done from ground one again. You cannot violate your own trial even if the results are smashing in order to reprehensibly (indeed unprecedented) boost your stock. You simply cannot do that. That is why the MD Anderson head did not even hesitate being allowed to be quoted. This is not questionable as to IF but to what degree (and I believe, severe) VIOLATION this is. For what purpose? Well it is for that (latter) reason SEC irrespective of anything else will INVESTIGATE and possibly (most probably halt). Severely fined will not do it. You cannot unblind data as before enrollment completion. You cannot release data (that are essentially daily reports) however promising and give the IMPRESSION as though you are at a different timeline, when enrollment has not yet been completed. In fact in that period of accumulating the data, you cannot ethically release what she released. Period
Objectively, this can go either way. If if we have news this is behind us. If we do not have news tomorrow or by end of week we will test 16.50.
38Million share outstanding is why this trades paper thin. A purchase of 5000 shares at opening tomorrow for example, would bring it to 1.00+ It is absurd. You are right who cares about another 10M. What we should be looking forward to are new plethora of BCBS accounts, any day that or buyout.
Yes, unbelievably and unexpectedly so. I don't get how just saying three patients are cancer free to date without the detailed accompanied, first enrollment stats and then they progress, for example, of those three, where they were prior to entering enrollment, what course of treatment received prior; all the accompanied actual clinical normal data that you would expect, etc. On her word, just doesn't cut it. And note the investment there is 95%+ retail. Quite astounding. Watch out!